Sector News

Pharma, take note: Millennials plan to spend more on meds, study says

October 17, 2020
Life sciences

The COVID-19 pandemic has millennials worried—and that has them planning to buy more prescription drugs in the future, new research finds.

WPP’s global media group, Mindshare, began surveying consumers in mid-March to find out what people were thinking about the then-emerging pandemic.

The finding? A lot of concerned consumers. But Mindshare also found that the more consumers worry about their health, the more they plan to spend on medications, Alexis Fragale, Mindshare’s director of consumer insights, said.

Overall, 77% of those surveyed planned to increase spending or spend the same amount on prescription medications.

However, when analyzed by generation, 26% of millennials—compared with only 9% of baby boomers—said they expect to increase their spending. It’s not that boomers will spend less; 85% expect to spend the same amount. They just aren’t likely to buy more. For comparison, 41% of millennials expect to keep their spending steady.

While researchers didn’t ask why, Fragale thinks that COVID-19 has had a substantial impact on people’s mental health. Prescription medicines are a broad category, and since respondents didn’t specify which medicines they were planning to buy, the drugs could be anything from contraceptives to antidepressants, she pointed out. Still, it’s an opportunity for pharma to reach the younger market.

Millennials are more inclined to pay more attention to their overall health, Fragale said. That means “they are probably are a bit more receptive to messaging and awareness.”

Other respondents Mindshare surveyed who are also changing plans to spend more on prescription medicine after COVID-19 include 37% of Hispanic consumers, 32% of Black consumers and 29% of Asian consumers, compared with 22% of white consumers.

Another part of the survey focused on Americans’ opinions on brand involvement in taking action during COVID-19. Pharma and healthcare tied at the top of the list with 71% of respondents saying they should be involved. The study characterized involvement as donation of supplies, such as basic necessities for communities in need, safe plans for customers upon reopening and tips on how to be healthy during quarantine.

So along with giving the expected donations and advocacy support during the pandemic, pharma companies should also consider content, Fragale said. While it may seem obvious to create more positive messages, third-party research shows that for people with chronic conditions, for instance, “optimism can play a key role in helping people cope with pain and counteract some of the negative emotions,” Fragale said.

“One thing that brands can do, at least in the chronic conditions space, is to not only keep that in mind for their creative messaging, but to show up in more positive media environments,” she added.

by Sharon Klahr Coey

Source: fiercepharma.com

 

Join the discussion!

Your email address will not be published. Required fields are marked *

Related News

January 23, 2021

Thermo Fisher Scientific acquires Novasep’s Henogen for $874.5m

Life sciences

Thermo Fisher Scientific has acquired Novasep’s viral vector manufacturing business in Belgium, Henogen, for about €725m ($874.5m) in cash. Henogen offers biotechnology firms, as well as biopharma customers contract manufacturing services for vaccines and therapies.

January 23, 2021

Lilly and Merus partner to develop T-Cell re-directing antibody therapies

Life sciences

Research and development group of Eli Lilly and Company, Loxo Oncology at Lilly, and clinical-stage oncology company Merus have announced a research collaboration and exclusive license agreement to develop T-Cell re-directing bispecific antibodies.

January 23, 2021

Adagene plans $125M IPO to go after cancer niches targeted by BMS and Pfizer

Life sciences

Chinese cancer biotech Adagene has filed to raise up to $125 million in a Nasdaq IPO. The listing will give Adagene the means to run early-phase clinical trials of antibodies against CD137 and CTLA-4.

Send this to a friend